Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma

Ovarian cancer immunotherapy: opportunities, progresses and challenges

Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand

The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting

Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology

Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28

What’s the place of immunotherapy in malignant mesothelioma treatments?

Presentation of tumour antigens by dendritic cells and challenges faced

Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus